Oaktree Capital Founder: Cautionary Investors May Miss Historic Investment Opportunities
On June 18, Howard Marks, co-founder of Oaktree Capital, discussed whether the current market is experiencing 'irrational exuberance' and the opportunities and risks under the AI investment boom in a recent podcast. He noted that the current market can be described using Alan Greenspan's words from 30 years ago; we are in a 'boom,' but no one can definitively say whether it is 'irrational.' Using SpaceX's impending IPO with a valuation of nearly $2 trillion as an example, he stated that deciding whether to participate and at what price is purely a matter of 'guessing,' and cannot be calculated like traditional value investing. Howard mentioned his favorite saying: 'Cautious individuals struggle to achieve great things.' He pointed out a current investment dilemma: investing in tech giants may lead to significant mistakes, but it can also yield remarkable successes. Those who hesitate out of fear of risk may miss out on the greatest investment opportunity in human history. In contrast, investors in traditional industries such as transportation, retail distribution, and real estate are unlikely to make catastrophic investment errors, but they also cannot seize the monumental benefits of this transformative era. In terms of valuation, Howard provided a key reference: the current price-to-earnings ratio of the S&P 500 is about 23 times, which is approximately 50% higher than the 80-year average of 16 times, but far lower than the 32 times during the 2000 internet bubble and below the 60 to 90 times level of the 'Nifty Fifty' era, indicating that overall it is 'high but not out of control.' Regarding AI investments, he proposed a three-tiered investment strategy: investing in large-scale tech companies is a low-risk approach due to their established business and cash flow; investing in vertical AI companies like Anthropic and OpenAI carries higher risks but also a higher probability of survival; while investing in early-stage startups is akin to gambling, where most will lose everything, but a few will become extremely wealthy. He advised investors to choose where they want to invest on the risk spectrum, mix different positions along the spectrum, and then determine what proportion these companies should represent in their overall investment portfolio.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BAE Systems wins Lockheed Martin contract to supply electronic warfare systems for F-35 jets
BAE Systems won a Lockheed Martin contract to supply electronic warfare systems for F-35 Lightning II fighter jets. Order covers production deliveries for F-35 Lots 20-22. Deal also includes retrofit systems to modernize older aircraft in the global F-35 fleet. BAE Systems has delivered more than 1,500 F-35 electronic warfare systems to date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BAE Systems plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061000PR_NEWS_USPR_____NE64821) on October 06, 2026, and is solely responsible for the information contained therein.
Japanese Yen: Range trade holds against US Dollar as Fed path questioned – Rabobank
BUZZ-GEO Group shares rise after completing $650 million debt refinancing
On October 6, shares of prison operator GEO Group (GEO.N) rose 2.6% in premarket trading to $33.19. The company conducted a debt refinancing, redeeming $650 million in senior secured notes due in 2029. Its $550 million revolving credit facility maturity was extended to July 2031. Earlier this week, the company agreed to sell its ICE processing center complex in Adelanto, California for $950 million. The company also recently increased its share repurchase authorization to $1.25 billion. As of the close of the previous trading day, the company's share price had more than doubled this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them for the convenience of readers only. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Updated: 2-ArriVent’s oral lung cancer therapy fails in late-stage clinical trial, shares plunge
In the first paragraph, stock information was added. Paragraphs 2 to 8 provide a detailed introduction to the disease and the clinical trial situation. Reuters, Oct. 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for treating rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, leading to its shares plunging by 63% in premarket trading. The therapy, firmonertinib, targets previously untreated advanced non-small cell lung cancer (NSCLC) patients who carry a gene mutation called the EGFR exon 20 insertion, which can promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC represents about 85% of all lung cancer cases. In the trial, according to independent reviewers, the 240mg dosage developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months in the chemotherapy group. Chief Executive Officer Bing Yao stated that the improvement in progression-free survival (defined as the length of time patients live without worsening or spread of disease) was not significant. "These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion-mutant NSCLC who are in urgent need of more effective treatments," said Yao. The company is evaluating the full data set to determine the most suitable development path for firmonertinib. ArriVent stated that no new safety signals were observed in the trial. The therapy has already been approved in China for non-small cell lung cancer patients carrying specific mutations. (For the convenience of non-English language speakers, Reuters has automated the translation of its reporting into several other languages. Due to possible errors or missing context in automated translation, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation feature.)
Crypto prices
More
